The estimated Net Worth of Lawrence D Kingsley is at least $4.72 Миллион dollars as of 6 May 2024. Mr. Kingsley owns over 339 units of Idexx Laboratories stock worth over $4,354,980 and over the last 20 years he sold IDXX stock worth over $0. In addition, he makes $362,808 as Independent Chairman of the Board at Idexx Laboratories.
Lawrence has made over 16 trades of the Idexx Laboratories stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 339 units of IDXX stock worth $166,198 on 6 May 2024.
The largest trade he's ever made was exercising 196,329 units of Idexx Laboratories stock on 24 August 2011 worth over $4,562,686. On average, Lawrence trades about 3,510 units every 41 days since 2004. As of 6 May 2024 he still owns at least 8,883 units of Idexx Laboratories stock.
You can see the complete history of Mr. Kingsley stock trades at the bottom of the page.
Lawrence D. Kingsley serves as Independent Chairman of the Board of the Company. He is currently serving as Lead Independent Director of the company. Mr. Kingsley served as Chairman of Pall Corporation from 2013 to 2015 and as Chief Executive Officer of Pall Corporation from 2011 to 2015, and he has served as an Advisory Director to Berkshire Partners LLC, a Boston-based investment firm, since spring of 2016. Before his experience at Pall, Mr. Kingsley was the Chief Executive Officer of IDEX Corporation, a company specializing in fluid and metering technologies, health and science technologies as well as fire, safety and other diversified products, from 2005 to 2011, and the Chief Operating Officer of IDEX from August 2004 to March 2005. From 1995 to 2004, he held various positions at Danaher Corporation of increasing responsibility, including Corporate Vice President and Group Executive from March 2004 to August 2004, President of Industrial Controls Group from April 2002 to July 2004, and President of Motion Group, Special Purpose Systems, from January 2001 to March 2002. Mr. Kingsley holds an undergraduate degree in Industrial Engineering and Management from Clarkson University and an M.B.A. from the College of William and Mary. As the former chief executive officers of Pall Corporation and IDEX Corporation, Mr. Kingsley successfully led high-technology, high-growth, multinational public companies and demonstrated his leadership and outstanding executive management and operational skills. Mr. Kingsley also brings strategic planning and financial expertise. Mr. Kingsley’s experience serving on other public company boards brings additional valuable perspectives to his Board service, including as our independent Lead Director.
As the Independent Chairman of the Board of Idexx Laboratories, the total compensation of Lawrence Kingsley at Idexx Laboratories is $362,808. There are 13 executives at Idexx Laboratories getting paid more, with Jonathan Ayers having the highest compensation of $8,309,800.
Lawrence Kingsley is 57, he's been the Independent Chairman of the Board of Idexx Laboratories since 2019. There are 13 older and 10 younger executives at Idexx Laboratories. The oldest executive at Idexx Laboratories, Inc. is M. Anne Szostak, 69, who is the Independent Director.
Lawrence's mailing address filed with the SEC is ONE IDEXX DRIVE, , WESTBROOK, ME, 04092.
Over the last 22 years, insiders at Idexx Laboratories have traded over $238,711,289 worth of Idexx Laboratories stock and bought 24,695 units worth $3,109,424 . The most active insiders traders include Stuart Essig, Johnny D Powers и Jonathan W Ayers. On average, Idexx Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of $4,641,291. The most recent stock trade was executed by M Anne Szostak on 5 September 2024, trading 500 units of IDXX stock currently worth $234,685.
idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an
Idexx Laboratories executives and other stock owners filed with the SEC include: